Cosciens Biopharma Inc. · TSX:CSCI
Cosciens Biopharma — Aeterna Zentaris — Investor Presentation (March 2021)
26 slides from Cosciens Biopharma's investor presentation, Mar 19, 2021
Slide 1: In Pursuit of Medical Innovations
zentaris.com NASDAQ: AEZS / TSX: AEZS ALTERNA ZENTARIS In Pursuit of Medical Innovations March 2021 Corporate Presentation
Slide 2: Forward-Looking Statements
Forward-Looking Statements ‘This document contains forward-looking statements (as defined by applicable securities legislation) made pursuant to the safe-harbor provision of the U.S. Securities Litigation Reform Act of 1995 and forward- looking information (as defined under applicable Canadian secur
Slide 3: Where We Are Today
Where We Are Today Investment Highlights Macimorelin Commercial and Development Partner European Commercial Partner First and only approved oral drug indicated Novo Nordisk is the global leader in growth Consilient Health is a privately owned for diagnosis of adult growth hormone Pais ea Gs pharma c
Slide 4: Growth Opportunities
Growth Opportunities Childhood-Onset Growth Hormone = A Pipeline Macimorelin as a Therapeutic Deficiency (CGHD) Testing Expansion a == = & be oa Leveraging AGHD approval Working with Advancing Therapeutic and compelling safety profile’ The University of Queensland and Vaccine Programs ALTERNA 4 1: M
Slide 5: Commercial and Development Diagnostic Pipeline
Commercial and Development Diagnostic Pipeline ———————. Commercial Rights Program Indication Preclinical Phase1 Phase2 Phase3 Commercial U.S./Canada Europe Israel ROW g | L by xe) ; _ Adult Growth Hormone Ak Gonsilient _fuMesaPia) YETERNA = Macimorelin Deficiency (AGHD) sav avery @ 2 Ty ZENTARIS fo)
Slide 6: Therapeutic and Vaccine Development Pipeline
Therapeutic and Vaccine Development Pipeline Program Indication Preclinical Phase1 Phase2 Phase3 —————— Program Highlights Neuromyelitis Optica ()) AIM Biologicals Spectrum Disorder [i In-licensed program in January 2021 — (NMOSD) Bi] o Undisclosed : i ir P Entered material transfer agreement and TH
Slide 7: Executing on Key 2021 Initiative
Executing on Key 2021 Initiative Building A Pipeline Beyond Diagnostics Developing Therapeutics and Vaccines to Secure Long-Term Growth
Slide 8: Potential treatment option for NMOSD
Julius-Maximilians UNIVERSITAT WURZBURG Potential treatment option for neuromyelitis optica spectrum disorder (NMOSD) NMOSD is an auto-antibody mediated inflammatory CNS orphan disorder with significant unmet need Entered exclusive license and R&D agreement with Julius-Maximilians- University of Wue
Slide 9: The Promise of Immunosuppressive Drugs
The Promise of Immunosuppressive Targeted, Physiological, Drugs Antigen-Specific 5 Immunosuppression Reduce disease symptoms May cause severe side effects Autoimmune Antigen-specific Diseases are Immunosuppression Enhanced by autoreactive effector T cells ® Ameliorated by protective effector T cells
Slide 10: Macimorelin as a Potential Therapeutic
Macimorelin as a Potential Therapeutic THE UNIVERSITY Q] oO OF QUEENSLAND Vo AUSTRALIA Entered Material Transfer Agreement Initially targeting as a potential University researchers to secure grants (MTA) with University of Queensland treatment for an undisclosed and conduct preclinical and clinical
Slide 11: Majority of motor neuron disease patients have GH deficiency
Majority of motor neuron disease (MND) patients have a moderate to marked GH deficiency
Slide 12: Delayed Clearance Parathyroid Hormone (DC-PTH) Fusion Polypeptides
Delayed Clearance Parathyroid Hormone (DC-PTH) Fusion Polypeptides Hypoparathyroidism oe aX PTH is a key regulating hormone Body produces abnormally low levels of PTH I) essential for calcium homeostasis and renal phosphate clearance oO Orphan indication — {S) Pel = Potential to be a self- @ 23 3/ a
Slide 13: Oral COVID-19 Vaccine Platform
aS UNIVERSITAT WURZBURG Paul-Ehrlich-Institut 2% Orally active live-attenuated bacterial vaccine based on the salmonella typhi Ty21a carrier strain Currently undergoing preclinical studies for the prevention of coronavirus diseases, including COVID-19 (SARS-CoV-2) Entered exclusive license and resea
Slide 14: Macimorelin: A Disruptive Oral Diagnostic
Macimorelin A Disruptive Oral Diagnostic G
Slide 15: Produced by the pituitary gland
Produced by the pituitary gland 15 (located at the base of the brain)
Slide 16: Childhood-Onset Growth Hormone Deficiency
Childhood-Onset Growth Hormone Deficiency Positive results in dose finding study M announced April 2020 Planned safety and efficacy study to commence early Q2 2021 American Association of Clinical Endocrinologists 2019 Guidelines “Because the test is simple, well tolerated ia ere 3 . P ith minimal s
Slide 17: Leveraging Clinical Success and Compelling Safety Profile
Leveraging Clinical Success and Compelling Safety Profile Expand Macimorelin Into CGHD Testing Through Use of Pediatric Development Plan Unified Clinical Protocol Agreed with U.S. FDA and EMA r ») YX EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH 17 ALTERNA ZENTARIS
Slide 18: Co-Development with Novo Nordisk
@ * Co-Development with Novo Nordisk (NN) ap * Aeterna Zentaris to be the responsible Sponsor overseeing the study \ * NN to fund 100% of budgeted Study P02 trial expenses up to €9 million novo nordisk Potential additional expenses to be shared Lf ETERNA
Slide 19: Study design: children and adolescents enrolled
Children and adolescents from 2 to less than 18 years of age with if suspected GHD to be enrolled 2 (Years) <18 2 100 subjects worldwide * Macimorelin GHST will be performed twice (for repeatability data) = Aoipre-pubertalland 40 pubertal subjects * Two standard GHSTs as controls: arginine (i.v.), c
Slide 20: Corporate Overview
Corporate Overview
Slide 21: Macimorelin Commercial Rights
Macimorelin Commercial Rights Actively seeking commercial partners in ROW novo nordisk License and Assignment Agreement Territories: United States and Canada Royalties on sales Sales milestones Aeterna Zentaris controls API supply chain and provides API Co-development for expansion into CGHD + Novo
Slide 22: Shares Outstanding and Average Volume
~120M ~20M Shares 3 month Outstanding’ Avg. Volume’
Slide 23: Management Team
Eckhard Guenther, PhD Managing Director / Senior VP, Business Development Aeterna Zentaris GmbH Leslie Auld, CPA, MBA Senior VP. Chief Financial Officer
Slide 24: Expected Value Driving Milestones
Expected Value Driving Milestones v Successful completion of Study P01 ile ae alcia all Planned start of CGHD Witt), Neves Norsk clinical safety and efficacy v European Licensing Agreement with study (AEZS-130-P02-— Planned submission - FDA Consilient Health Ltd. multi-national, including U.S.) and
Slide 25: Investment Summary
Investment Summary Executing on key 2021 initiative to build a pipeline beyond diagnostics — seca See ocr rr eaot ner ter eens ea acese + DC-PTH fusion polypeptides as a potential treatment for primary hypoparathyroidism Macimorelin is the only approved oral product for diagnosis of adult growth hor
Slide 26: Investor & Media Relations
zentaris.com NASDAQ: AEZS / TSX: AEZS ALTERNA ZENTARIS In Pursuit of Medical Innovations Investor & Media Relations JTC Team 833.475.8247 aezs@jtcir.com
Aeterna Zentaris — Investor Presentation (March 2021) on 6ix